GlaxoSmithKline's (GSK) Fluarix Quadrivalent Receives FDA Approval
Get Alerts GSK Hot Sheet
Price: $42.99 --0%
Overall Analyst Rating:
NEUTRAL ( Up)
Dividend Yield: 4.8%
Revenue Growth %: +29.4%
Overall Analyst Rating:
NEUTRAL ( Up)
Dividend Yield: 4.8%
Revenue Growth %: +29.4%
Join SI Premium – FREE
GlaxoSmithKline plc (NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has approved FLUARIX QUADRIVALENT (Influenza Virus Vaccine) for the immunisation of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine. Fluarix Quadrivalent is the first intramuscular vaccine to cover against four influenza strains.
Scientists classify the influenza strains that cause seasonal flu as A or B strains. Currently administered trivalent (three-strain) flu vaccines help protect against the two A virus strains most common in humans and the B strain expected to be predominant in a given year. But since the year 2000, two B virus strains (Victoria and Yamagata) have co-circulated to varying degrees each season. Various degrees of mismatch have occurred between the B strain included in trivalent vaccines and the B strain that actually circulated, causing an increased risk of influenza-related morbidity across all age groups – children, adults and the elderly. Fluarix Quadrivalent helps protect against the two A strains and adds coverage against a second B strain.
Scientists classify the influenza strains that cause seasonal flu as A or B strains. Currently administered trivalent (three-strain) flu vaccines help protect against the two A virus strains most common in humans and the B strain expected to be predominant in a given year. But since the year 2000, two B virus strains (Victoria and Yamagata) have co-circulated to varying degrees each season. Various degrees of mismatch have occurred between the B strain included in trivalent vaccines and the B strain that actually circulated, causing an increased risk of influenza-related morbidity across all age groups – children, adults and the elderly. Fluarix Quadrivalent helps protect against the two A strains and adds coverage against a second B strain.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WuXi Biologics Reports Solid 2023 Annual Results
- Praxis Precision Medicines (PRAX) Announces Pricing of $200 Mln Public Offering
- TFF Pharmaceuticals (TFFP) Announces Updated Data from TFF TAC and TFF VORI Clinical Programs
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!